First Time Loading...

Y-mAbs Therapeutics Inc
NASDAQ:YMAB

Watchlist Manager
Y-mAbs Therapeutics Inc Logo
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
Watchlist
Price: 12.85 USD 2.31% Market Closed
Updated: May 23, 2024

Y-mAbs Therapeutics Inc
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Y-mAbs Therapeutics Inc
Total Equity Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Total Equity Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
Total Equity
$99.2m
CAGR 3-Years
-27%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Total Equity
$8B
CAGR 3-Years
-16%
CAGR 5-Years
N/A
CAGR 10-Years
5%
Gilead Sciences Inc
NASDAQ:GILD
Total Equity
$17.5B
CAGR 3-Years
-3%
CAGR 5-Years
-4%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Total Equity
$5B
CAGR 3-Years
-19%
CAGR 5-Years
-14%
CAGR 10-Years
-14%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Equity
$18.5B
CAGR 3-Years
27%
CAGR 5-Years
31%
CAGR 10-Years
31%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Equity
$27B
CAGR 3-Years
31%
CAGR 5-Years
23%
CAGR 10-Years
28%

See Also

What is Y-mAbs Therapeutics Inc's Total Equity?
Total Equity
99.2m USD

Based on the financial report for Mar 31, 2024, Y-mAbs Therapeutics Inc's Total Equity amounts to 99.2m USD.

What is Y-mAbs Therapeutics Inc's Total Equity growth rate?
Total Equity CAGR 5Y
-5%

Over the last year, the Total Equity growth was -8%. The average annual Total Equity growth rates for Y-mAbs Therapeutics Inc have been -27% over the past three years , -5% over the past five years .